Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,770 across all filing types
Latest filing 2026-04-14 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于金陵药业股份有限公司2025年度持续督导定期现场检查报告
Audit Report / Information Classification · 80% confidence The document is a detailed onsite inspection report (“现场检查报告”) prepared by the sponsor (中信证券) for the ongoing supervision of a listed company, covering governance, internal control, disclosure, use of funds, performance checks, etc. It is not a simple announcement or a summary; it is the full supervisory/audit‐style report itself. This aligns with the Audit Report / Information category (AR) for standalone audit or regulatory inspection reports outside of full annual/quarterly filings.
2026-04-14 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2025年度保荐工作报告
Regulatory Filings Classification · 45% confidence The document is a 2025 annual sponsorship work report (“保荐工作报告”) prepared by the sponsor (CITIC Securities) on its regulatory review, supervision, and compliance actions for Jinling Pharmaceutical. This is not an earnings release, annual report, management discussion, proxy statement, or other specific category. It is a required regulatory submission by the sponsor but does not match any narrowly defined filing type. Hence it defaults to the general Regulatory Filings category.
2026-04-14 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年向特定对象发行股票持续督导保荐总结报告书
Share Issue/Capital Change Classification · 80% confidence The document is a detailed sponsor (保荐人) summary report (“持续督导保荐总结报告书”) concerning Jinling Pharmaceutical’s 2023 directed A-share issuance: it spells out the number of shares, issue price, net proceeds, regulatory approvals and continuous supervision work. This falls under share issuance/capital change filings rather than an earnings release, management discussion, or annual report. Therefore the best fit is Share Issue/Capital Change (SHA).
2026-04-14 Chinese
金陵药业股份有限公司第九届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 24th meeting of the 9th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, and voting results on various reports and proposals such as the 2025 President's Work Report, Board Work Report, Financial Statements, Profit Distribution Plan, Internal Control Self-Evaluation Report, and others. It also references that the detailed reports and documents are published on a designated website and newspapers on March 31, 2026. The document itself is a formal announcement of board meeting decisions rather than the full reports or financial statements. The length is 3756 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2026-03-30 Chinese
2025年年度审计报告
Regulatory Filings
2026-03-30 Chinese
金陵药业股份有限公司关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the provision for asset impairment for the fiscal year 2025. It details the amounts of impairment provisions for various asset categories such as bad debts, inventory, fixed assets, goodwill, etc., and explains the accounting basis and impact on the company's 2025 net profit. The document also mentions the board and audit committee meetings approving the provision. The length is about 3200 characters, which is relatively short and the document is an announcement of the impairment provision decision rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or a regulatory compliance filing. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting estimates and provisions that does not fit other specific categories.
2026-03-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.